10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers

Lancet Oncol. 2018 Mar;19(3):285-287. doi: 10.1016/S1470-2045(18)30105-0.

¹ Paediatric and Adolescent Oncology Drug Development, The Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK; Innovative Therapy for Children with Cancer, Europe. Electronic address: [email protected].
² KickCancer, Brussels, Belgium; Unite 2 Cure, Europe.
³ Innovative Therapy for Children with Cancer, Europe; Cancer Research UK Clinical Trials Unit Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; SIOPE Brussels, Belgium.
⁴ Unite 2 Cure, Europe; Fondatioun Kriibskrank Kanner, Strassen, Luxembourg.
⁵ Paediatric and Adolescent Oncology Drug Development, The Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
⁶ Unite 2 Cure, Europe; Imagine for Margo, Paris, France.
⁷ Innovative Therapy for Children with Cancer, Europe; SIOPE Brussels, Belgium; Department of Clinical Research, Gustave Roussy, Paris-Saclay University, Villejuif, France.

No abstract available

MeSH terms